Cybin Inc. (CYBN)
(Real Time Quote from BATS)
$0.30 USD
0.00 (0.03%)
Updated Jul 22, 2024 10:18 AM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYBN 0.30 0.00(0.03%)
Will CYBN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CYBN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYBN
What Makes Cybin Inc. (CYBN) a New Buy Stock
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
CYBN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
Brian's Big Idea on Biotech
Other News for CYBN
Cybin price target lowered by $1 at TD Cowen, here's why
Here's What You Missed in Cannabis, Psychedelics This Week
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights